1. Medtech Insight
  2. >>Business
  3. >>Deals

Biodesix Buys US Laboratory Assets From Oncimmune

 
• By Catherine Longworth

Biodesix is expanding its portfolio of lung cancer diagnostic tests and acquiring the US assets of UK company Oncimmune.

M&A, Mergers and Acquisitions. US Dollar texture. - Illustration

US liquid biopsy firm Biodesix Inc. is expanding its lung cancer diagnostic portfolio and picking up the US assets of UK diagnostics company Oncimmune Ltd.. 

The agreement is valued at up to $28m over the next five years, the companies said.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Somnee AI-Powered Sleep Wearable Raises $10M Seed Round

 
• By Natasha Barrow

The $10m seed extension funding round will be used to launch the second-generation wearable headband with the added SmartSleep AI operating system.

Intuitive Surgical Projects $165M Tariff Hit In 2025, Says Wait-And-See On Mitigation

 
• By Shubham Singh

Despite near-term cost pressures, Intuitive Surgical is expanding manufacturing and R&D in North America and Europe to meet demand for Ion, X and Xi systems.

Three Steps To Investor Heaven For Medtech Founders: Articulate, Explain, Clarify

 
• By Ashley Yeo

Capital remains available for good healthtech projects, but it is more concentrated and harder to find than of late. Founders and inventors must know how to unlock it. The BioWales 2025 investor panel told them where they could be going wrong.